

Non-Interventional Prospective Study on the Role of Donor vs Recipient NK Cell Allo-reactivity in Haploidentical Hematopoietic Transplantation for Hematologic Malignancies

EBMT
European Society for Blood and Marrow Transplantation

Inclusion criteria

- DIAGNOSIS: **AML and ALL**
- TYPE OF TRANSPLANT: **Mismatched related donor with two or more HLA anti-gen mismatches**
- NO AGE RESTRICTION
- ANY TYPE OF PROFYLAXIS
- STEM CELL SOURCE: **PB, BM and PB + BM**
- ANY TYPE OF CONDITIONING REGIMEN
- START PATIENT INCLUSION: **September 2012**

Exclusion criteria

- ALL DIAGNOSIS OTHER THAN AML AND ALL

Take this opportunity to include your patients in this important study!

The Immunobiology Working Party (IWP) is conducting a study to evaluate the role of donor vs recipient NK cell allo-reactivity in haploidentical hematopoietic transplantation for hematologic malignancies. Donor-versus-recipient NK cell allo-reactivity is a key therapeutic element in the success of HLA haplotype mismatched ("haploidentical") hematopoietic stem cell transplants for acute myeloid leukemia. The role of NK cell allo-reactivity will be assessed separately in T cell depleted and T cell replete transplants in the following two patient populations: 1) AML or ALL in any remission; 2) AML or ALL in chemo-resistant relapse.

Should you have eligible patients for this study, please contact the EBMT Data Office Leiden at immunewp.ebmt@lumc.nl

EBMT Data Office Leiden, LUMC Postzone S-5-P,, P.O. Box 9600, NL-2300 RC Leiden , The Netherlands . Fax : 49-180-500-290-623 *or* +49-711-4900-8723

NK cell allo-reactivity in ALL and AML
EBMT/IWP Non-Interventional Prospective Study

CENTRE REGISTRATION

STUDY

A Non-Interventional Prospective Study to evaluate the impact of donor versus recipient NK cell allo-reactivity on disease relapse and event free survival in patients who undergo haplo-identical transplantation in European centres.

Centre eligibility criteria:

Do you regularly treat patients diagnosed with either ALL or AML? ☐ Yes

Is allogeneic HSCT from a haplo-identical donor a standard option in your centre? ☐ Yes

Can you provide high quality HLA typing for donor and patient (4 digits)? ☐ Yes

Will you perform KIR genotyping/phenotyping for the donor by PCR on DNA? ☐ Yes

You must answer Yes to all questions in order to participate in this study

CENTRE

EBMT Centre Identification Code (CIC) .....

Centre Name and Address .....

.....

.....

Contact person .....

Email address .....

Does your centre want to participate in this non-interventional prospective study?

☐ Yes, How many patients do you expect to include in this study per year? I_I_I

Proposed start date: .... - .... - ....

dd *mm* *yyyy*

☐ No, reason:……...

IDENTIFICATION & SIGNATURE

When participating: I agree to include all consecutive patients who agree to participate in this study and declare that the inclusion of any patient in this study will not affect the management of this patient.

..... Signature

..... Name

Please send the completed form to the CLWP Data Office in Leiden ASAP by using Fax: **+49 180 500 290 623 / +49 711 4900 8723** (fax to e-mail system) or E-mail: **immunewp.ebmt@lumc.nl**